Small-Molecule Heterocyclic Compounds: Gq-Biased Agonists for the 5-HT2A Receptor in Neuropsychiatric Treatment.
Journal
ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073
Informations de publication
Date de publication:
09 Nov 2023
09 Nov 2023
Historique:
received:
04
10
2023
pmc-release:
09
11
2024
medline:
17
11
2023
pubmed:
17
11
2023
entrez:
17
11
2023
Statut:
epublish
Résumé
Addressing the significant challenges of treating depression, anxiety, and substance abuse, this Patent Highlight explores the development of innovative small-molecule heterocyclic compounds as Gq-biased agonists of the 5-HT2A receptor. Unlike traditional treatments, these compounds selectively activate 5-HT2A-mediated Gq signaling, excluding related receptors like 5-HT2B and 5-HT2C. This selectivity suggests a more targeted and efficient therapeutic approach. The discovery of these compounds could herald a new era in neuropsychiatric treatment, promising safer, faster, and more effective interventions. Further research will illuminate their potential and applicability in clinical settings.
Identifiants
pubmed: 37974947
doi: 10.1021/acsmedchemlett.3c00444
pmc: PMC10641896
doi:
Types de publication
Editorial
Langues
eng
Pagination
1498-1500Informations de copyright
Published 2023 by American Chemical Society.
Déclaration de conflit d'intérêts
The author declares no competing financial interest.
Références
J Psychoactive Drugs. 2023 Sep-Oct;55(4):501-517
pubmed: 36127639
J Psychopharmacol. 2023 Sep;37(9):849-865
pubmed: 37650489
J Psychoactive Drugs. 2023 Aug 24;:1-17
pubmed: 37615379
J Psychiatr Pract. 2023 Sep 01;29(5):345-353
pubmed: 37678363
J Psychopharmacol. 2023 Sep;37(9):876-890
pubmed: 37572027
Psychiatry Res. 2023 Sep;327:115349
pubmed: 37523886